GENERAL COMMENTS
Thank you for the opportunity of reviewing this interesting manuscript which addresses the importance of the benefits of using Lipase in the diagnosis of acute pancreatitis. The authors show lipase to be superior to amylase and that the use of lipase alone would result in a significant financial saving. Whilst this is not a completely novel observation, most units in the UK do not measure lipase routinely. This manuscript will provide additional evidence that lipase should be quantified.
There are a couple of minor points: 1. The authors should indicate what they used as a gold standard for diagnosis of AP against which the sensitivity and specificity of lipase and amylase were calculated. 2. I suggest omitting the data on chronic pancreatitis from this paper as lipase and amylase are not routinely used for this purpose. I think that the authors should develop a larger series of patients with CP in which amylase and lipase have been measured to determine if, either alone or in combination, they can aid in the diagnosis of this condition. 
REVIEWER

Reviewer Comments
General Comments This is a retrospective observational study describing the superiority of serum lipase over serum amylase in the diagnosis of acute pancreatitis. However, the authors have included both acute and chronic pancreatitis patients in the study cohort and this detracts from the conclusions of the study. Separation of the acute and chronic pancreatitis patients (or removal of the chronic pancreatitis patients), along with some minor restructuring of the manuscript would enhance the authors' message. Further, as the authors point out, the superiority of serum lipase over serum amylase in the diagnosis of acute pancreatitis is already well-described and recommended by various medical bodies; and this study supports that literature. RESULTS & CONCLUSIONS 1. The diagnosis of chronic pancreatitis is not based on elevated serum amylase or lipase levels alone but also relies on symptoms and radiological imaging. Are the authors including acute on chronic pancreatitis patients as these patients probably represent a different spectrum/cohort of patients; and would be corroborated by the fact that the authors describe a reduced degree of enzyme elevation in chronic pancreatitis, as compared to acute pancreatitis? Separation of acute and chronic pancreatitis would be helpful in further delineating which patients should undergo measurement of serum lipase levels. 2. Do the authors have available data concerning time from symptom onset to presentation or assessment of serum amylase/lipase levels? A delay in presentation is likely to be an underlying factor behind the lack of elevated serum amylase levels in certain patients, given the quick peak and decrease in amylase levels in response to pancreatic injury. 3. Was the Glasgow score used as described in the manuscript or was it the more commonly utilised Modified Glasgow scoring system? And what was the breakdown of the scores? 4. Table 2 describes that there were two acute pancreatitis patients and one chronic pancreatitis patients with normal lipase and amylase levels -how were these patients diagnosed with pancreatitis? 5. Further discussion of, or a basic table describing, the nonpancreatitis aetiologies that led to elevated serum amylase/lipase levels would be helpful to aid the reader in understanding the important differential diagnoses when using these serum assays. 6. Given that a plethora of information already suggests that serum lipase levels are superior to serum amylase levels for the diagnosis of acute pancreatitis, and the assays are of similar cost, why are they not utilized in more UK centres? A discussion of the potential limitations of serum lipase assays and the underlying reasons for its lack of utilization would be useful. Please see page 5, last para: The diagnosis of pancreatitis was based on the following criteria: clinical features (abdominal pain and vomiting) together with the elevation of serum concentrations of pancreatic enzymes (amylase and / or lipase), a value three times greater than normal.
VERSION 1 -AUTHOR RESPONSE
2. I suggest omitting the data on chronic pancreatitis from this paper as lipase and amylase are not routinely used for this purpose. I think that the authors should develop a larger series of patients with CP in which amylase and lipase have been measured to determine if, either alone or in combination, they can aid in the diagnosis of this condition.
We have omitted the data with respect to chronic pancreatitis (please see manuscript).
Reviewer 2: This is a retrospective observational study describing the superiority of serum lipase over serum amylase in the diagnosis of acute pancreatitis. However, the authors have included both acute and chronic pancreatitis patients in the study cohort and this detracts from the conclusions of the study. Separation of the acute and chronic pancreatitis patients (or removal of the chronic pancreatitis patients), along with some minor restructuring of the manuscript would enhance the authors' message. Further, as the authors point out, the superiority of serum lipase over serum amylase in the diagnosis of acute pancreatitis is already well-described and recommended by various medical bodies; and this study supports that literature.
1. The diagnosis of chronic pancreatitis is not based on elevated serum amylase or lipase levels alone but also relies on symptoms and radiological imaging. Are the authors including acute on chronic pancreatitis patients as these patients probably represent a different spectrum/cohort of patients; and would be corroborated by the fact that the authors describe a reduced degree of enzyme elevation in chronic pancreatitis, as compared to acute pancreatitis? Separation of acute and chronic pancreatitis would be helpful in further delineating which patients should undergo measurement of serum lipase levels. As suggested by Reviewer 1, we have removed the cohort of chronic pancreatitis patients (please see manuscript), and only included results from patients admitted with acute pancreatitis.
2. Do the authors have available data concerning time from symptom onset to presentation or assessment of serum amylase/lipase levels? A delay in presentation is likely to be an underlying factor behind the lack of elevated serum amylase levels in certain patients, given the quick peak and decrease in amylase levels in response to pancreatic injury. We do not have data on symptom onset to presentation with respect to assessment of serum amylase/lipase levels. The aim of this study was to assess the diagnostic accuracy of serum amylase and lipase in the diagnosis of pancreatitis in patients at presentation, irrespective of onset of symptoms.
3. Was the Glasgow score used as described in the manuscript or was it the more commonly utilised Modified Glasgow scoring system? And what was the breakdown of the scores? We did use the modified Glasgow scoring system (please see text, correction has been done). There were 29 patients who scored more than 3 i.e. predicted severe pancreatitis.
Please see page 6, line 4: All patients diagnosed with acute pancreatitis were then scored using the modified Glasgow Scoring System and had C-reactive….
Please see page 8, para 2: With respect to patients with acute pancreatitis, 68 (58%) patients were males, and the median age of presentation was 46 (17 -90) years. There were 29 (19.2%) patients predicted to have severe pancreatitis based on the modified Glasgow Scoring System........ Table 2 describes that there were two acute pancreatitis patients and one chronic pancreatitis patients with normal lipase and amylase levels -how were these patients diagnosed with pancreatitis?
4.
We have removed patients with chronic pancreatitis from this study. With regards to four patients with normal amylase and lipase levels, they were diagnosed with radiological imaging (computer tomography).
Please see page 9, para 1: ….. Overall, there were four patients that had normal levels of both lipase and amylase, and these patients were diagnosed with acute pancreatitis following CT scan.
5. Further discussion of, or a basic table describing, the non-pancreatitis aetiologies that led to elevated serum amylase/lipase levels would be helpful to aid the reader in understanding the important differential diagnoses when using these serum assays. A table has been done, please refer to Table 2 . Pathology Raised lipase and amylase levels (n = 12) Raised lipase with normal amylase levels (n = 6) Raised amylase with normal lipase levels (n = 14) Ruptured abdominal aortic aneurysm 7 3 5 Perforated duodenal ulcer 4 2 4 Cholecystitis 0 0 2 Intestinal obstruction 1 1 3 6. Given that a plethora of information already suggests that serum lipase levels are superior to serum amylase levels for the diagnosis of acute pancreatitis, and the assays are of similar cost, why are they not utilized in more UK centres? A discussion of the potential limitations of serum lipase assays and the underlying reasons for its lack of utilization would be useful. This has been included in the discussion section.
Please see page 13, line 1: …… Although there is good published literature with respect to measurement of lipase levels alone in diagnosing acute pancreatitis, this practice is still not observed in many UK centers. One possible explanation is the easy availability of assessment of amylase levels by local chemical pathology laboratories. 20 In addition, some authors have proposed that both tests are necessary to effectively diagnose pancreatitis, 21 while other state that it is not necessary to perform both for diagnostic purposes. 22 Although lipase levels are considered to be specific for acute pancreatitis, non-specific elevations of lipase have been reported in almost as many disorders as amylase, thus decreasing its specificity. ….. -The reviewer completed the checklist but made no further comments.
